At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
LENZ Therapeutics
Market Closed 12-12 16:00:00 EST
18.14
-6.36
-25.96%
盘后18.59
+0.45+2.47%
19:58 EST
High24.79Low15.70Vol6.63M
Open24.66D1 Closing24.50Amplitude37.10%
Mkt Cap567.60MTradable Cap284.66MTotal Shares31.29M
T/O124.21MT/O Rate42.24%Tradable Shares15.69M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Press Release: Sobi to acquire Arthrosi Therapeutics, strengthening pipeline for the potential treatment of gout
Dow Jones  ·  12-14 04:53
Press Release: Sobi to acquire Arthrosi Therapeutics, strengthening pipeline for the potential treatment of gout
Lenz Therapeutics- Aware of Recent Adverse Event Report Submitted to the FDA - SEC Filing
THOMSON REUTERS  ·  12-13 05:26
Lenz Therapeutics- Aware of Recent Adverse Event Report Submitted to the FDA - SEC Filing
Lenz Therapeutics - Adverse Event Reporting System Database Describing a Retinal Tear in a Patient Using Vizz (Aceclidine Ophthalmic Solution) 1.44%
THOMSON REUTERS  ·  12-13 05:26
Lenz Therapeutics - Adverse Event Reporting System Database Describing a Retinal Tear in a Patient Using Vizz (Aceclidine Ophthalmic Solution) 1.44%
Structure Therapeutics Is Maintained at Overweight by Morgan Stanley
Dow Jones  ·  12-13 01:23
Structure Therapeutics Is Maintained at Overweight by Morgan Stanley
Mineralys Therapeutics’ Phase 3 Launch-HTN Trial of Lorundrostat Recognized in Inaugural Journal of the American Medical Association (JAMA) “Research of the Year” Roundup
GlobeNewswire  ·  12-13 00:00
Mineralys Therapeutics’ Phase 3 Launch-HTN Trial of Lorundrostat Recognized in Inaugural Journal of the American Medical Association (JAMA) “Research of the Year” Roundup
Structure Therapeutics Is Maintained at Market Outperform by Citizens
Dow Jones  ·  12-12 21:05
Structure Therapeutics Is Maintained at Market Outperform by Citizens
RBC Cuts Price Target on Applied Therapeutics to $0.25 From $1, Keeps Sector Perform, Speculative Risk
MT Newswires Live  ·  12-12 20:01
RBC Cuts Price Target on Applied Therapeutics to $0.25 From $1, Keeps Sector Perform, Speculative Risk
Autolus Therapeutics Price Target Maintained With a $10.00/Share by Needham
Dow Jones  ·  12-12 19:12
Autolus Therapeutics Price Target Maintained With a $10.00/Share by Needham
Argenica Therapeutics' AI-Driven Reanalysis of Phase 2 Stroke Trial Shows Commercially Meaningful Benefit, Says Euroz Hartleys
MT Newswires Live  ·  12-12 12:03
Argenica Therapeutics' AI-Driven Reanalysis of Phase 2 Stroke Trial Shows Commercially Meaningful Benefit, Says Euroz Hartleys
Serina Therapeutics Strengthens Leadership Team with Appointment of Dr. Joshua Thomas as VP, Head of Chemistry
GlobeNewswire  ·  12-12
Serina Therapeutics Strengthens Leadership Team with Appointment of Dr. Joshua Thomas as VP, Head of Chemistry
Press Release: Oruka Therapeutics Announces New Board Member and Board Transition
Dow Jones  ·  12-12
Press Release: Oruka Therapeutics Announces New Board Member and Board Transition
Press Release: Structure Therapeutics Announces Closing of Upsized $747.5 Million Public Offering of ADSs and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional ADSs
Dow Jones  ·  12-12
Press Release: Structure Therapeutics Announces Closing of Upsized $747.5 Million Public Offering of ADSs and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional ADSs
Plus Therapeutics Is Maintained at Buy by D. Boral Capital
Dow Jones  ·  12-12
Plus Therapeutics Is Maintained at Buy by D. Boral Capital
Why Are Shares Of Atossa Therapeutics Up Today?
Benzinga_recent_news  ·  12-12
Why Are Shares Of Atossa Therapeutics Up Today?
Cadrenal Therapeutics Acquires VLX-1005, a First-in-Class Phase 2 12-LOX Inhibitor for Patients with Heparin-Induced Thrombocytopenia (HIT)
GlobeNewswire  ·  12-11
Cadrenal Therapeutics Acquires VLX-1005, a First-in-Class Phase 2 12-LOX Inhibitor for Patients with Heparin-Induced Thrombocytopenia (HIT)
Plus Therapeutics Expands CNSide Assay Platform to State of California
GlobeNewswire  ·  12-11
Plus Therapeutics Expands CNSide Assay Platform to State of California
Denali Therapeutics Shares Fall in Premarket on Share Offering Price
Dow Jones  ·  12-10
Denali Therapeutics Shares Fall in Premarket on Share Offering Price
Wedbush Adjusts Viridian Therapeutics Price Target to $47 From $42, Maintains Outperform Rating
MT Newswires Live  ·  12-10
Wedbush Adjusts Viridian Therapeutics Price Target to $47 From $42, Maintains Outperform Rating
Viridian Therapeutics Is Maintained at Outperform by Wedbush
Dow Jones  ·  12-10
Viridian Therapeutics Is Maintained at Outperform by Wedbush
Structure Therapeutics Prices $650 Million Upsized Public Offering
MT Newswires Live  ·  12-10
Structure Therapeutics Prices $650 Million Upsized Public Offering

Introduction

Company Name.
Therapeutics
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.
Issue price:
--